RG

Redmile Group Portfolio holdings

AUM $1.49B Turnover 10.26%
1-Year Est. Return 208.7%
This Fund
S&P 500
This Quarter Est. Return
-10.28%
1 Year Est. Return
+208.7%
3 Year Est. Return
+777.5%
5 Year Est. Return
+1,114.43%
10 Year Est. Return
+23,630.52%
AUM
$1.32B
AUM Growth
+$99.8M
Cap. Flow
+$327M
Cap. Flow %
24.74%
Top 10 Hldgs %
52.92%
Holding
77
New
22
Increased
20
Reduced
12
Closed
19
Avg Time Held
0.6 years
Top 10 Avg Time Held
0.5 years
Top 20 Avg Time Held
0.4 years

Top Buys

Rank Stock Value
1
MDVN
MEDIVATION, INC.
MDVN
+$86.8M
2
RAD
Rite Aid Corporation
RAD
+$67.2M
3
PEN icon
Penumbra
PEN
+$63.2M
4
SAGE icon
Sage Therapeutics
SAGE
+$52.5M
5
INCY icon
Incyte
INCY
+$50.3M

Top Sells

Rank Stock Value
1
BHC icon
Bausch Health
BHC
+$85.4M
2
AGN
Allergan plc
AGN
+$41.5M
3
KYTH
KYTHERA BIOPHARMACEUTICALS, INC COM
KYTH
+$36.3M
4
HCA icon
HCA Healthcare
HCA
+$35.4M
5
ABBV icon
AbbVie
ABBV
+$34.3M

Sector Composition

Rank Sector Weight
1 Healthcare 88.54%
2 Miscellaneous 9.13%
3 Communication Services 1.09%
4 Industrials 1%
5 Technology 0.23%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow Held Since
FOLD icon
1
DELISTED
Amicus Therapeutics
FOLD
$117M 8.83%
8,332,930
+2,035,407
+32% +$31.9M
2013 Q2
9 quarters
CLVS
2
DELISTED
Clovis Oncology, Inc.
CLVS
$88.1M 6.67%
957,634
+198,155
+26% +$17.1M
2013 Q2
9 quarters
ARRY icon
3
DELISTED
Array Biopharma Inc
ARRY
$80.9M 6.13%
17,750,510
+4,126,890
+30% +$24.5M
2013 Q2
9 quarters
MDVN
4
DELISTED
MEDIVATION, INC.
MDVN
$74.5M 5.64%
+1,752,642
New +$86.8M
2015 Q3
0 quarters
INCY icon
5
Incyte
INCY
$22.7B
$67.7M 5.13%
613,598
+448,603
+272% +$50.3M
2015 Q2
1 quarter
TEVA icon
6
Teva Pharmaceutical Industries Limited
TEVA
$48B
$64.2M 4.87%
1,137,559
+170,200
+18% +$11M
2015 Q1
2 quarters
SGEN
7
DELISTED
Seagen Inc. Common Stock
SGEN
$53.6M 4.06%
1,390,173
+860,974
+163% +$38.8M
2014 Q3
4 quarters
ITCI icon
8
DELISTED
Intra-Cellular Therapies Inc.
ITCI
$53M 4.01%
1,322,592
+712,421
+117% +$23.2M
2014 Q1
6 quarters
PEN icon
9
Penumbra
PEN
$12.6B
$51M 3.86%
+1,562,587
New +$63.2M
2015 Q3
0 quarters
RAD
10
DELISTED
Rite Aid Corporation
RAD
$49M 3.71%
+403,570
New +$67.2M
2015 Q3
0 quarters
SAGE icon
11
DELISTED
Sage Therapeutics
SAGE
$48.4M 3.66%
1,142,864
+852,514
+294% +$52.5M
2015 Q2
1 quarter
WCG
12
DELISTED
Wellcare Health Plans, Inc.
WCG
$44.3M 3.36%
+514,273
New +$45.1M
2015 Q3
0 quarters
CMRX icon
13
DELISTED
Chimerix, Inc.
CMRX
$40.8M 3.09%
1,067,978
+368,553
+53% +$18.2M
2013 Q2
9 quarters
CNC icon
14
Centene
CNC
$34.5B
$40.5M 3.07%
+1,494,920
New +$50M
2015 Q3
0 quarters
BMRN icon
15
BioMarin Pharmaceuticals
BMRN
$10.6B
$38.8M 2.94%
368,775
+161,031
+78% +$21.5M
2015 Q2
1 quarter
ZSPH
16
DELISTED
ZS PHARMA INC COMS TK (DE)
ZSPH
$33.8M 2.56%
514,107
+211,119
+70% +$12.7M
2014 Q3
4 quarters
ATRA icon
17
Atara Biotherapeutics
ATRA
$95M
$33M 2.5%
41,991
+27,085
+182% +$33M
2014 Q4
3 quarters
PTLA
18
DELISTED
Portola Pharmaceuticals, Inc.
PTLA
$32.8M 2.49%
769,641
+616,941
+404% +$29.8M
2015 Q2
1 quarter
NDRM
19
DELISTED
NeuroDerm Ltd. Ordinary Shares
NDRM
$30.2M 2.29%
+1,462,699
New +$30M
2015 Q3
0 quarters
NSTG
20
DELISTED
NanoString Technologies, Inc.
NSTG
$22.2M 1.68%
1,385,641
-74,101
-5% -$1.16M
2013 Q3
8 quarters
CLDX icon
21
Celldex Therapeutics
CLDX
$2.18B
$20.6M 1.56%
130,268
+128,084
+5,865% +$36.3M
2014 Q4
3 quarters
DBVT icon
22
DBV Technologies S.A. American Depositary Shares
DBVT
$566M
$19M 1.44%
+53,282
New +$21M
2015 Q3
0 quarters
DVAX icon
23
DELISTED
Dynavax Technologies
DVAX
$17.8M 1.35%
+724,348
New +$20.5M
2015 Q3
0 quarters
INSM icon
24
Insmed
INSM
$21.3B
$17.6M 1.33%
947,966
+80,620
+9% +$2.01M
2014 Q3
4 quarters
MODN icon
25
DELISTED
MODEL N, INC.
MODN
$14.4M 1.09%
1,443,278
– –
2013 Q4
7 quarters
1
2 3 4

Similar funds

FCM
Fairholme Capital Management South Miami, Florida $1.49B AUM 28.35% 1-Year Est. Return
MM
Main Management San Francisco, California $1.49B AUM 22.28% 1-Year Est. Return
WA
WBH Advisory Baltimore, Maryland $1.49B AUM 20.41% 1-Year Est. Return
ACB
Aristotle Capital Boston Boston, Massachusetts $1.49B AUM 32.81% 1-Year Est. Return
LCS
Levin Capital Strategies New York $1.49B AUM 30.44% 1-Year Est. Return
GAM
Gemmer Asset Management Walnut Creek, California $1.49B AUM 42.66% 1-Year Est. Return
MFWP
Mosaic Family Wealth Partners St. Louis, Missouri $1.49B AUM 26.43% 1-Year Est. Return
PMG
ProVise Management Group Clearwater, Florida $1.49B AUM 21.79% 1-Year Est. Return

Redmile Group's Q3 2015 Portfolio in Review

As of Q3 2015, Redmile Group held 77 positions worth $1.32B, up 8.2% from $1.22B the previous quarter. Its ten largest holdings account for 53% of the portfolio.

Redmile Group deployed $327M of net new capital in Q3 2015, opening 22 new positions and adding to 20 existing holdings. Its largest new stake was MEDIVATION, INC.: 1,752,642 shares worth $74.5M.

By sector, the portfolio is most concentrated in Healthcare at 89% of assets, up from 87% a quarter earlier, followed by Miscellaneous and Communication Services.

On the sell side, the largest reduction was Jazz Pharmaceuticals, an estimated $25.7M trimmed.

  • Redmile Group's largest Q3 2015 buy was MEDIVATION, INC.: 1,752,642 shares worth $74.5M.
  • Redmile Group added most to Sage Therapeutics in Q3 2015, an estimated $52.5M increase.
  • Redmile Group's biggest Q3 2015 reduction was Jazz Pharmaceuticals, cutting an estimated $25.7M.
  • Redmile Group fully exited Bausch Health in Q3 2015, selling an estimated $85.4M.
  • Redmile Group's ten largest holdings make up 53% of its $1.32B portfolio in Q3 2015.
  • Redmile Group opened 22 new positions and closed 19 in Q3 2015.
  • Redmile Group's portfolio value rose 8.2% quarter-over-quarter to $1.32B.

Based on Redmile Group's 13F filing for Q3 2015, filed 17 Nov 2015.